Baxter Healthcare was presented the award for the HDx enabled by Theranova haemodialysis (HD) therapy by James & Wells Partner, Jonathan Lucas at the James & Wells Health Tech Week Gala Dinner.

More than 1700 New Zealanders receive haemodialysis treatment. Patients with end-stage renal disease on haemodialysis are at increased mortality risk compared to the general population.

Conventional haemodialysis is effective at removing small toxins, such as urea, but is ineffective at removing a class of uremic toxins known as large middle molecules. Large middle molecules may affect a range of biological functions, including inflammation, secondary immunodeficiency and cardiovascular (heart disease) risk.

Theranova is an innovative dialyser. It more closely mimics the natural kidney compared with other dialysis membranes. Theranova extends the range of toxins that can be filtered from the blood during haemodialysis for the first time without significant albumin loss. Once these toxins have been effectively removed, the patient is at less risk of infections and hospitalisation.

Source: James & Wells